Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Conditions:   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Germline BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   High Grade Fallopian Tube Serous A denocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Sensitive Fallopian Tube Carcinoma;   Platinum-Sensitive Ovarian Carcinoma;   Platinum-Sensitive Primary  Peritoneal Carcinoma;   Primary Peritoneal Carcinosarcoma;   Primary Peritoneal Clear Cell Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Primary Peritoneal Transitional Cell Carcinoma;   Primary Peritoneal Undifferentiated Carcinoma;   Recurrent Fallopian  Tube Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Ovarian Serous Adenocarcinoma;   Recurrent Ovarian Transitional Cell Carcinoma;   Recurrent Primary Peritoneal&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Ovarian Cancer;   Ovarian Neoplasms;   Ovarian Carcinosarcoma;   Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Fallopian Tube Cancer;   Fallopian Tube Neoplasms;   Primary Peritoneal Carcinoma;   Primary Per itoneal Serous Adenocarcinoma Interventions:   Drug: Paclitaxel;   Drug: TAK228 Sponsors:   Imperial College London;   Takeda Pharmaceuticals Internat...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinosarcoma | Fallopian Tube Cancer | Immunotherapy | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research | Serous Carcinoma